Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Timothy Lyons and Alicia Jenkins.
Timothy Lyons
Connection Strength
3.630
Alicia Jenkins
  1. 'Lipoproteins, glycoxidation and diabetic angiopathy'. Diabetes Metab Res Rev. 2004 Sep-Oct; 20(5):349-68.
    View in: PubMed
    Score: 0.256
  2. Serum urate and cardiovascular events in the DCCT/EDIC study. Sci Rep. 2021 07 09; 11(1):14182.
    View in: PubMed
    Score: 0.206
  3. Vitamin D Metabolites and Binding Protein Predict Preeclampsia in Women with Type 1 Diabetes. Nutrients. 2020 Jul 10; 12(7).
    View in: PubMed
    Score: 0.192
  4. Haptoglobin Phenotype Modulates Lipoprotein-Associated Risk for Preeclampsia in Women With Type 1 Diabetes. J Clin Endocrinol Metab. 2019 10 01; 104(10):4743-4755.
    View in: PubMed
    Score: 0.182
  5. Pre-enrichment of modified low density lipoproteins with alpha-tocopherol mitigates adverse effects on cultured retinal capillary cells. Curr Eye Res. 1999 Aug; 19(2):137-45.
    View in: PubMed
    Score: 0.180
  6. Response to Comment on Kelly et al. Subclinical First Trimester Renal Abnormalities Are Associated With Preeclampsia in Normoalbuminuric Women With Type 1 Diabetes. Diabetes Care 2018;41:120-127. Diabetes Care. 2018 06; 41(6):e102-e103.
    View in: PubMed
    Score: 0.166
  7. Subclinical First Trimester Renal Abnormalities Are Associated With Preeclampsia in Normoalbuminuric Women With Type 1 Diabetes. Diabetes Care. 2018 01; 41(1):120-127.
    View in: PubMed
    Score: 0.160
  8. Circulating adipokines are associated with pre-eclampsia in women with type 1 diabetes. Diabetologia. 2017 12; 60(12):2514-2524.
    View in: PubMed
    Score: 0.158
  9. Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis. Diabetes Rev (Alex). 1997; 5(4):365-391.
    View in: PubMed
    Score: 0.151
  10. Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes. J Lipid Res. 2016 Feb; 57(2):310-7.
    View in: PubMed
    Score: 0.140
  11. Trace elements as predictors of preeclampsia in type 1 diabetic pregnancy. Nutr Res. 2015 May; 35(5):421-30.
    View in: PubMed
    Score: 0.134
  12. Clinical correlates of serum pigment epithelium-derived factor in type 2 diabetes patients. J Diabetes Complications. 2014 May-Jun; 28(3):353-9.
    View in: PubMed
    Score: 0.123
  13. Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. J Diabetes Complications. 2013 Sep-Oct; 27(5):447-53.
    View in: PubMed
    Score: 0.118
  14. Serum inflammatory markers and preeclampsia in type 1 diabetes: a prospective study. Diabetes Care. 2013 Jul; 36(7):2054-61.
    View in: PubMed
    Score: 0.115
  15. Plasma lipoproteins and preeclampsia in women with type 1 diabetes: a prospective study. J Clin Endocrinol Metab. 2012 May; 97(5):1752-62.
    View in: PubMed
    Score: 0.108
  16. Serum carotenoids and fat-soluble vitamins in women with type 1 diabetes and preeclampsia: a longitudinal study. Diabetes Care. 2011 Jun; 34(6):1258-64.
    View in: PubMed
    Score: 0.101
  17. Increased serum kallistatin levels in type 1 diabetes patients with vascular complications. J Angiogenes Res. 2010 Sep 22; 2:19.
    View in: PubMed
    Score: 0.097
  18. Increased coated-platelet levels in chronic haemodialysis patients. Nephrology (Carlton). 2009 Apr; 14(2):148-54.
    View in: PubMed
    Score: 0.088
  19. Coated-platelet levels in patients with Type 1 and with Type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008 Aug; 81(2):e8-10.
    View in: PubMed
    Score: 0.083
  20. Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. J Diabetes Complications. 2008 May-Jun; 22(3):153-63.
    View in: PubMed
    Score: 0.082
  21. Glycation does not alter LDL-induced secretion of tissue plasminogen activator and plasminogen activator inhibitor-1 from human aortic endothelial cells. Ann N Y Acad Sci. 2005 Jun; 1043:379-89.
    View in: PubMed
    Score: 0.067
  22. In vivo glycated low-density lipoprotein is not more susceptible to oxidation than nonglycated low-density lipoprotein in type 1 diabetes. Metabolism. 2004 Aug; 53(8):969-76.
    View in: PubMed
    Score: 0.064
  23. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci. 2004 Mar; 45(3):910-8.
    View in: PubMed
    Score: 0.062
  24. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int. 2003 Sep; 64(3):817-28.
    View in: PubMed
    Score: 0.060
  25. Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia. Diabetes Care. 2003 Mar; 26(3):810-8.
    View in: PubMed
    Score: 0.058
  26. Serum pigment epithelium-derived factor: Relationships with cardiovascular events, renal dysfunction, and mortality in the Veterans Affairs Diabetes Trial (VADT) cohort. J Diabetes Complications. 2019 10; 33(10):107410.
    View in: PubMed
    Score: 0.045
  27. Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D. J Lipid Res. 2019 08; 60(8):1432-1439.
    View in: PubMed
    Score: 0.045
  28. Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D. J Lipid Res. 2018 05; 59(5):872-883.
    View in: PubMed
    Score: 0.041
  29. Data on carotid intima-media thickness and lipoprotein subclasses in type 1 diabetes from the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC). Data Brief. 2016 Mar; 6:33-8.
    View in: PubMed
    Score: 0.035
  30. Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes. Atherosclerosis. 2016 Jan; 244:93-100.
    View in: PubMed
    Score: 0.035
  31. Plasma total homocysteine and carotid intima-media thickness in type 1 diabetes: a prospective study. Atherosclerosis. 2014 Sep; 236(1):188-195.
    View in: PubMed
    Score: 0.032
  32. Elevated circulation levels of an antiangiogenic SERPIN in patients with diabetic microvascular complications impair wound healing through suppression of Wnt signaling. J Invest Dermatol. 2014 Jun; 134(6):1725-1734.
    View in: PubMed
    Score: 0.031
  33. Apolipoprotein-defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. J Diabetes Complications. 2013 Nov-Dec; 27(6):627-32.
    View in: PubMed
    Score: 0.030
  34. Therapeutic effects of PPARa agonists on diabetic retinopathy in type 1 diabetes models. Diabetes. 2013 Jan; 62(1):261-72.
    View in: PubMed
    Score: 0.028
  35. High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes. Diabetes Care. 2012 Jun; 35(6):1333-40.
    View in: PubMed
    Score: 0.027
  36. LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses. J Diabetes Complications. 2011 Mar-Apr; 25(2):73-82.
    View in: PubMed
    Score: 0.024
  37. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care. 2008 Oct; 31(10):2006-12.
    View in: PubMed
    Score: 0.021
  38. Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J Lipid Res. 2008 Apr; 49(4):847-55.
    View in: PubMed
    Score: 0.020
  39. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis. 2007 Feb; 190(2):359-69.
    View in: PubMed
    Score: 0.018
  40. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation. 2005 May 17; 111(19):2446-53.
    View in: PubMed
    Score: 0.017
  41. Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort. J Diabetes Complications. 2005 Jan-Feb; 19(1):18-25.
    View in: PubMed
    Score: 0.016
  42. Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses. Metabolism. 2004 Oct; 53(10):1296-304.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.